173 related articles for article (PubMed ID: 35053532)
1. Temozolomide-Acquired Resistance Is Associated with Modulation of the Integrin Repertoire in Glioblastoma, Impact of α5β1 Integrin.
Sani S; Pallaoro N; Messe M; Bernhard C; Etienne-Selloum N; Kessler H; Marinelli L; Entz-Werle N; Foppolo S; Martin S; Reita D; Dontenwill M
Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053532
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.
Wang H; Cai S; Bailey BJ; Reza Saadatzadeh M; Ding J; Tonsing-Carter E; Georgiadis TM; Zachary Gunter T; Long EC; Minto RE; Gordon KR; Sen SE; Cai W; Eitel JA; Waning DL; Bringman LR; Wells CD; Murray ME; Sarkaria JN; Gelbert LM; Jones DR; Cohen-Gadol AA; Mayo LD; Shannon HE; Pollok KE
J Neurosurg; 2017 Feb; 126(2):446-459. PubMed ID: 27177180
[TBL] [Abstract][Full Text] [Related]
3. The TNF receptor family member Fn14 is highly expressed in recurrent glioblastoma and in GBM patient-derived xenografts with acquired temozolomide resistance.
Hersh DS; Harder BG; Roos A; Peng S; Heath JE; Legesse T; Kim AJ; Woodworth GF; Tran NL; Winkles JA
Neuro Oncol; 2018 Sep; 20(10):1321-1330. PubMed ID: 29897522
[TBL] [Abstract][Full Text] [Related]
4. Integrin α5β1 plays a critical role in resistance to temozolomide by interfering with the p53 pathway in high-grade glioma.
Janouskova H; Maglott A; Leger DY; Bossert C; Noulet F; Guerin E; Guenot D; Pinel S; Chastagner P; Plenat F; Entz-Werle N; Lehmann-Che J; Godet J; Martin S; Teisinger J; Dontenwill M
Cancer Res; 2012 Jul; 72(14):3463-70. PubMed ID: 22593187
[TBL] [Abstract][Full Text] [Related]
5. alpha5beta1 integrin antagonists reduce chemotherapy-induced premature senescence and facilitate apoptosis in human glioblastoma cells.
Martinkova E; Maglott A; Leger DY; Bonnet D; Stiborova M; Takeda K; Martin S; Dontenwill M
Int J Cancer; 2010 Sep; 127(5):1240-8. PubMed ID: 20099278
[TBL] [Abstract][Full Text] [Related]
6. Targeted therapy based on p53 reactivation reduces both glioblastoma cell growth and resistance to temozolomide.
Forte IM; Indovina P; Iannuzzi CA; Cirillo D; Di Marzo D; Barone D; Capone F; Pentimalli F; Giordano A
Int J Oncol; 2019 Jun; 54(6):2189-2199. PubMed ID: 31081046
[TBL] [Abstract][Full Text] [Related]
7. Integrins and p53 pathways in glioblastoma resistance to temozolomide.
Martin S; Janouskova H; Dontenwill M
Front Oncol; 2012; 2():157. PubMed ID: 23120745
[TBL] [Abstract][Full Text] [Related]
8. The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma.
Banelli B; Carra E; Barbieri F; Würth R; Parodi F; Pattarozzi A; Carosio R; Forlani A; Allemanni G; Marubbi D; Florio T; Daga A; Romani M
Cell Cycle; 2015; 14(21):3418-29. PubMed ID: 26566863
[TBL] [Abstract][Full Text] [Related]
9. Acquired temozolomide resistance in human glioblastoma cell line U251 is caused by mismatch repair deficiency and can be overcome by lomustine.
Stritzelberger J; Distel L; Buslei R; Fietkau R; Putz F
Clin Transl Oncol; 2018 Apr; 20(4):508-516. PubMed ID: 28825189
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy of cold atmospheric plasma (CAP) with temozolomide in the treatment of U87MG glioblastoma cells.
Gjika E; Pal-Ghosh S; Kirschner ME; Lin L; Sherman JH; Stepp MA; Keidar M
Sci Rep; 2020 Oct; 10(1):16495. PubMed ID: 33020527
[TBL] [Abstract][Full Text] [Related]
11. DNA-methylation-mediated activating of lncRNA SNHG12 promotes temozolomide resistance in glioblastoma.
Lu C; Wei Y; Wang X; Zhang Z; Yin J; Li W; Chen L; Lyu X; Shi Z; Yan W; You Y
Mol Cancer; 2020 Feb; 19(1):28. PubMed ID: 32039732
[TBL] [Abstract][Full Text] [Related]
12. EFEMP1 induces γ-secretase/Notch-mediated temozolomide resistance in glioblastoma.
Hiddingh L; Tannous BA; Teng J; Tops B; Jeuken J; Hulleman E; Boots-Sprenger SH; Vandertop WP; Noske DP; Kaspers GJ; Wesseling P; Wurdinger T
Oncotarget; 2014 Jan; 5(2):363-74. PubMed ID: 24495907
[TBL] [Abstract][Full Text] [Related]
13. Exosomal transfer of long non-coding RNA SBF2-AS1 enhances chemoresistance to temozolomide in glioblastoma.
Zhang Z; Yin J; Lu C; Wei Y; Zeng A; You Y
J Exp Clin Cancer Res; 2019 Apr; 38(1):166. PubMed ID: 30992025
[TBL] [Abstract][Full Text] [Related]
14. miR-126-3p sensitizes glioblastoma cells to temozolomide by inactivating Wnt/β-catenin signaling via targeting SOX2.
Luo W; Yan D; Song Z; Zhu X; Liu X; Li X; Zhao S
Life Sci; 2019 Jun; 226():98-106. PubMed ID: 30980849
[TBL] [Abstract][Full Text] [Related]
15. YKL-40 downregulation is a key factor to overcome temozolomide resistance in a glioblastoma cell line.
Akiyama Y; Ashizawa T; Komiyama M; Miyata H; Oshita C; Omiya M; Iizuka A; Kume A; Sugino T; Hayashi N; Mitsuya K; Nakasu Y; Yamaguchi K
Oncol Rep; 2014 Jul; 32(1):159-66. PubMed ID: 24842123
[TBL] [Abstract][Full Text] [Related]
16. NBM-BMX, an HDAC8 Inhibitor, Overcomes Temozolomide Resistance in Glioblastoma Multiforme by Downregulating the β-Catenin/c-Myc/SOX2 Pathway and Upregulating p53-Mediated MGMT Inhibition.
Tsai CY; Ko HJ; Chiou SJ; Lai YL; Hou CC; Javaria T; Huang ZY; Cheng TS; Hsu TI; Chuang JY; Kwan AL; Chuang TH; Huang CF; Loh JK; Hong YR
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072831
[TBL] [Abstract][Full Text] [Related]
17. miR-20a mediates temozolomide-resistance in glioblastoma cells via negatively regulating LRIG1 expression.
Wei J; Qi X; Zhan Q; Zhou D; Yan Q; Wang Y; Mo L; Wan Y; Xie D; Xie J; Yang S
Biomed Pharmacother; 2015 Apr; 71():112-8. PubMed ID: 25960225
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of cyclin E1 overcomes temozolomide resistance in glioblastoma by Mcl-1 degradation.
Liang H; Chen Z; Sun L
Mol Carcinog; 2019 Aug; 58(8):1502-1511. PubMed ID: 31045274
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-128-3p Enhances the Chemosensitivity of Temozolomide in Glioblastoma by Targeting c-Met and EMT.
Zhao C; Guo R; Guan F; Ma S; Li M; Wu J; Liu X; Li H; Yang B
Sci Rep; 2020 Jun; 10(1):9471. PubMed ID: 32528036
[TBL] [Abstract][Full Text] [Related]
20. Integrin α5β1 and p53 convergent pathways in the control of anti-apoptotic proteins PEA-15 and survivin in high-grade glioma.
Renner G; Janouskova H; Noulet F; Koenig V; Guerin E; Bär S; Nuesch J; Rechenmacher F; Neubauer S; Kessler H; Blandin AF; Choulier L; Etienne-Selloum N; Lehmann M; Lelong-Rebel I; Martin S; Dontenwill M
Cell Death Differ; 2016 Apr; 23(4):640-53. PubMed ID: 26470725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
